Lincoln Pharmaceuticals Reports 55% Surge In Net Profit For March Quarter
Lincoln Pharmaceuticals reported a 55% surge in consolidated net profit to Rs 18.88 crore for the March quarter of 2023-24, driven by strong sales.16-05-2024
16-05-2024
LINCOLN PHARMACEUTICALS LTD. - 531633 - FINANCIAL HIGHLIGHTS WITH RESPECT TO AUDITED FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED MARCH 31, 2024
FINANCIAL HIGHLIGHTS WITH RESPECT TO AUDITED FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED MARCH 31, 202416-05-2024
LINCOLN PHARMACEUTICALS LTD. - 531633 - Corporate Action-Board approves Dividend
Recommended a final Dividend of Rs.1.80/- (i.e.18%) per equity share of face value of Rs.10/- each for the financial year ended 31st March, 2024 for approval of the member at the ensuring AGM of the Company.16-05-2024
LINCOLN PHARMACEUTICALS LTD. - 531633 - Audited Financial Results For Quarter And Year Ended 31St March, 2024
Audited Financial Results for Quarter and year Ended 31st March,2024.16-05-2024
LINCOLN PHARMACEUTICALS LTD. - 531633 - Board Meeting Outcome for Outcome Of Audited Financial Results For Quarter And Year Ended On 31St March, 2024
outcome of Audited Financial Results for Quarter and year Ended on 31st March, 202416-05-2024
LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copies of Newspaper Advertisement as required under Rule 6 of IEPF Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 and amendments thereof,15-05-2024
LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Q4 FY24 post results earning call details15-05-2024
LINCOLN PHARMACEUTICALS LTD. - 531633 - Corporate Action-Board to consider Dividend
Meeting of the Board of the Directors is scheduled to be held on May 16, 2024 to consider and approve Audited Financial Results of the Company and recommendation of Dividend on equity shares of the Company if any.08-05-2024
LINCOLN PHARMACEUTICALS LTD. - 531633 - Board Meeting Intimation for Intimation Of Board Meeting To Consider And Approve Audited (Standalone & Consolidated) Financial Results Of The Company For The Quarter And Year Ended On March 31, 2024.
LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2024 ,inter alia, to consider and approve Audited (standalone and consolidated) financial results of the Company for the quarter and year ended on March 31, 2024.08-05-2024
LINCOLN PHARMACEUTICALS LTD. - 531633 - Certificate Under Regulation 40 (9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Please find enclosed herewith the Certificate from the Practicing Company Secretary under Regulation 40(9) of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 for the year ended March 31, 2024.22-04-2024